Quarterly Results, Dividend Growth, Expanding Portfolio, New Product Offerings, and FDA Approvals - Research Report on Boston Scientific, Zimmer Holdings, Stryker, St. Jude, and Hologic

NEW YORK, August 1, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Boston Scientific Corporation (NYSE: BSX), Zimmer Holdings, Inc. (NYSE: ZMH), Stryker Corp. (NYSE: SYK), St. Jude Medical Inc. (NYSE: STJ), and Hologic Inc. (NASDAQ: HOLX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Boston Scientific Corporation Research Report

On July 25, 2013, Boston Scientific Corp. (Boston Scientific) reported its Q2 2013 financial results, with sales of $1.8 billion, down 1% YoY. The Company's adjusted EPS of $0.18 exceeded its previous guidance of $0.14 to $0.17. Adjusted net income totaled $247 million or $0.18 per share, compared to $239 million or $0.17 per share in Q2 2012. Commenting on the results, Mike Mahoney, President and Chief Executive Officer of Boston Scientific, said, "We are pleased with our improved performance during the quarter. As we continue to expand our portfolio, our team is inspired to deliver meaningful innovation to more patients globally." For Q3 2013, the Company anticipates sales to be in the range of $1,700 million to $1,760 million, and GAAP earnings in the range of $0.03 to $0.05 per share. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/BSX]

--

Zimmer Holdings, Inc. Research Report

On July 25, 2013, Zimmer Holdings Inc. (Zimmer Holdings) reported its Q2 2013 financial results, with net sales of $1.2 billion, reflecting a rise of 4.0% YoY, and adjusted diluted EPS of $1.43, representing a growth of 6.7% YoY. "In the second quarter, Zimmer delivered strong sales results, driven by our innovative new product offerings and growth in key geographies," said David Dvorak, Zimmer Holdings President and Chief Executive Officer. "We are confident that the Company will sustain this accelerated top line performance in the second half of the year. Through disciplined capital deployment and our commitment to operational excellence, we will remain focused on creating value for our stockholders." The Company updated its full-year 2013 revenue growth guidance to range between 4% and 5% YoY, up from its previous guidance range of 2.5% to 4.5% YoY. The Company also revised its diluted EPS guidance to range from $4.70 to $4.80 (on a reported basis) and $5.70 to $5.80 (on an adjusted basis). The Full Research Report on Zimmer Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/ZMH]

--

Stryker Corp. Research Report

On July 15, 2013, Stryker Corp. (Stryker) announced that its Board of Directors has approved a quarterly dividend of $0.27 per share. The Company reported that the dividend will be payable on October 31, 2013, to shareholders of record as on September 30, 2013. Stryker also stated that the quarterly dividend represented a growth of 25% YoY. The Full Research Report on Stryker Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/SYK]

--

St. Jude Medical Inc. Research Report

On July 22, 2013, St. Jude Medical Inc. (St. Jude Medical) announced that Stefan Widensohler, Proprietor, Chief Executive Officer and President of the KRAUTH Medical Group, has been appointed to the Company's Board of Directors, effective July 19, 2013. According to the Company, Mr. Widensohler served as a Director of St. Jude Medical from 2001 to 2010 and has been an active investor and board member of various medical technology companies. Commenting on the appointment, St. Jude Medical Chairman, President and Chief Executive Officer Daniel J. Starks said, "We are very pleased to have Stefan Widensohler return to the St. Jude Medical board of directors. Stefan brings to the board substantial international healthcare expertise that will be invaluable to our board as St. Jude Medical continues to grow on a global basis." The Full Research Report on St. Jude Medical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/STJ]

--

Hologic Inc. Research Report

On July 23, 2013, Hologic Inc. (Hologic) announced that its Aptima HPV assay for use on the Company's fully-automated Panther system has received an approval from the US Food and Drug Administration (FDA). The Company stated that Aptima HPV mRNA based assay is a nucleic acid amplified test that detects 14 high-risk strains of human papillomavirus (HPV) associated with cervical cancer and precancerous lesions and has demonstrated significantly improved specificity with no compromise in disease detection. "Our Panther system is a world-class automation solution for a broad range of molecular diagnostic laboratories," said Rohan Hastie, Senior Vice President and General Manager, Diagnostics. "Expanding the menu of available assays on Panther builds on our platform-centric strategy of delivering workflow efficiencies and revenue generating opportunities to our laboratory partners." The Full Research Report on Hologic Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/HOLX]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports